Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
Trial details
- Registry ID
- NCT04429555
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as MN-166
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSNCT04429555 | MediciNova | Phase 2 | Completed | 2022-06-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |